STAT3 and lung carcinoma: STAT3 signaling within tumor and immune cells shapes the TME; the vast majority of lung cancer studies report that STAT3 drives tumor-promoting inflammation while impairing anti-tumor immunity [18,19,58,59,60,61,62,63,64,65,66].